Tumor Agnostic Agents: Targeted Therapies Makes Inroads in Solid Tumors Tough-to-treat Gi and Melanoma Patients See Promising Survival Benefits

Tumor Agnostic Agents: Targeted Therapies Makes Inroads in Solid Tumors Tough-to-treat Gi and Melanoma Patients See Promising Survival Benefits is organized by Projects In Knowledge Inc. (PIK).

Release Date: 1/27/2023                    
Termination Date: 1/26/2024

Learning Objective(s):
• Review immune co-signaling components that represent novel therapeutic targets for enhancing immune-mediated destruction of cancer.
• Evaluate recent clinical data for new and emerging checkpoint-targeting therapeutic approaches.     

Additional details will be posted as soon as information is available.

0.5 MOC | 0.5 IPCE | 0.5 AMA PRA Category 1 Credit™ | 0.5 Contact Hours | 0.1 CEU